Most patients with cystic fibrosis (CF) who are past childhood are chronically colonized by Pseudomonas aeruginosa (12) . As the median survival time of patients increases, demands for alternative antibiotics for treatment of infections also increase. Until recently, parenteral treatment with ,B-lactam antibiotics and aminoglycosides was the only option. The introduction of the fluorinated quinolones made oral treatment of infections caused by P. aeruginosa a therapeutic possibility (48) . Among the available quinolones, ciprofloxacin has shown the highest in vitro activity against Pseudomonas spp. (38) and has also been beneficial in patients with CF (19, 48) . Earlier pharmacokinetic studies have shown that the disposition of many antibiotics in CF patients is different from that in healthy individuals (11) . We therefore investigated the pharmacokinetics of ciprofloxacin given orally and intravenously (i.v.) to CF patients with mild pulmonary exacerbations and to healthy volunteers. The patients were enrolled from a larger study comparing the efficacy and tolerance of oral and i.v. ciprofloxacin (48) .
MATERIALS AND METHODS Subjects. Five healthy male volunteers (21 to 31 years old) and 18 CF patients (17 to 27 years old) were included in the study after giving informed consent. Table 1 shows the basic characteristics of these individuals. The CF patients had all been diagnosed in infancy or childhood (mean time since diagnosis, 21 years) and had had pathological sweat tests (chloride, 280 mmol/liter). They were all colonized with P. aeruginosa, in 14 patients including mucoid strains. All patients received basic treatment with inhalation of mucolytic agents and supplementation of pancreatic enzymes and fat-soluble vitamins in water dispersion. They did not receive antacids or minerals during treatment. Two patients had diabetes mellitus, and one had cirrhosis of the liver. One mg/kg twice daily for 10 to 14 days as a 20-min infusion), and 13 received treatment with 15 mg/kg twice daily orally for at least 10 days. Venous blood samples were obtained from an indwelling plastic catheter in the contralateral arm before infusion; at 5, 10, 15, 30, and 45 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 h after the end of the first infusion; and, if treatment continued, on the fifth to seventh study days. In connection with oral dosing, venous blood samples were collected in an identical manner except for the exclusion of samples taken 5 and 10 min after ingestion of drug. Urine was collected quantitatively from the start of infusion or tablet intake until 2, 4, 6, 8, and 12 h after the administrations. Serum and urine aliquots were frozen within 1 h of collection and stored at -20°C until assayed.
Antibiotic assays. Concentrations of ciprofloxacin in serum and urine were determined with high-performance liquid chromatography (35) . The intra-and interassay imprecisions (coefficients of variation) were below 5% in both serum (at concentrations of 0.1 and 1 mg/liter) and urine (at concentrations of 10.0 and 100.0 mg/liter), and the detection limit was 0.01 mg/liter.
Pharmacokinetic calculations. Pharmacokinetic analysis was performed according to noncompartmental methods Statistical analysis. The results of the groups were calculated as group means. The standard deviation (SD) was used as an indicator of variability except for basic characteristics (Table 1) , for which range was used. Differences between groups were evaluated with the two-tailed Wilcoxon's rank sum test for unpaired observations. Wilcoxon's rank sum test for paired observations was used for statistical comparison in the multiple-dose study. Significance was defined as P < 0.05.
RESULTS
Laboratory tests and adverse reactions. The GFR measured as iohexol clearance was larger in patients than in volunteers regardless of correction for body surface area (Table 1) . Healthy volunteers did not experience any adverse reactions, and no laboratory changes were detected. In the orally treated patients, no adverse reactions were noted. Two patients in the i.v.-treated group had to discontinue treatment, one because of conjunctivitis and localized urticaria after the third dose and one because of diarrhea. Two other patients reacted with local itching and thrombophlebitis but were nonetheless able to continue treatment. Among the patients, a transient small but significant rise in serum aminotransferase activities was seen with both i.v. and oral treatments.
i.v. administration. The mean concentrations of ciprofloxacin in serum after the first i.v. doses in patients and volunteers are presented in Fig. 1 except for (40) or by direct secretion of parent compound from intestinal mucosa (52) . The renal elimination of many antibiotics is enhanced in CF subjects, usually in relation to the increased GFR (21, 22 (47) . Furthermore, the renal tubular function in CF patients may be altered, as evidenced by disturbances in renal sodium handling (7, 46) . The larger CLM of ciprofloxacin in our patients conflicts with some earlier findings (10, 30) but can be explained by the fact that our patients were in a comparatively good clinical status, as indicated by normal to high GFR and mild clinical and biochemical markers of infection. In chronically severely ill CF patients, renal function decreases. Chronic infection may exert an inhibitory effect on hepatic metabolism through bacterial toxins (17) . Data similar to ours have been presented elsewhere: increased CLr, CLR, and V.. were noted among CF patients under stable conditions (5) .
Multiple dosing. Our data indicate changes in pharmacokinetics during the course of treatment. In addition to a slightly increased AUC on the fifth to seventh study days, probably due to accumulation, t1,2 increased during oral treatment. In earlier studies of multiple-dose kinetics of ciprofloxacin in patients with CF but without acute infection, results were conflicting. In one study, no differences were seen between the 1st and 14th study days with oral doses of 750 and 1,000 mg twice daily (50) . Another investigation observed decreased CLR and increased AUC on the eighth study day with 500 mg doses every 8 h (42 
